Search results
Results from the Tech24 Deals Content Network
rVSV-ZEBOV. VSV-EBOV or rVSV-ZEBOV, sold under the brand name Ervebo, is a vaccine based on the vesicular stomatitis virus which was genetically modified to express a surface glycoprotein of Zaire Ebola virus. [ 16][ 17] In November 2019, the European Commission granted a conditional marketing authorization. [ 18]
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
From 1962 to 2022 there have been 157 recorded cases of the infection in United States, only 4 of those 157 individuals survived the disease. A combination of drugs have shown effectiveness in survivors. The rate drops significantly to >50% with treatment. The rate dropped significantly to 10% with effective treatments. Eradicated .
A stockpile of half-a-million Ebola vaccine doses was established by Gavi and other global health partners in 2019 for use in outbreaks of haemorrhagic fever, which has an average fatality rate of ...
A month ago the European Union issued marketing authorization for a vaccine to prevent the Ebola virus in adults, and now the FDA has approved it. While noting that Ebola cases in the US have been ...
The vaccine, developed by the pharmaceutical giant Merck, is known as Ervebo. It's the first human Ebola vaccine to be approved by the EU. Ervebo was first engineered by the Public Health Agency ...
The use of fetal tissue in vaccine development is the practice of researching, developing, and producing vaccines through growing viruses in cultured (laboratory-grown) cells that were originally derived from human fetal tissue. [ 1] Since the cell strains in use originate from abortions, [ 2] there has been opposition to the practice and the ...
BY LAURAN NEERGAARD WASHINGTON (AP) -- New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster ...